According to a new report LAMEA Genetic Testing Market, published by KBV research, the LAMEA Genetic Testing Market would witness market growth of 12.3% CAGR during the forecast period (2019-2025).
The Brazil market dominated the LAMEA Cardiovascular Disease Diagnosis Market by Country in 2018, growing at a CAGR of 12.3 % during the forecast period. The Argentina market is expected to witness a CAGR of 14.5% during (2019 - 2025). Additionally, The UAE market is expected to witness a CAGR of 12.6% during (2019 - 2025).
The Molecular Testing market dominated the UAE Genetic Testing Market by Technology in 2018, growing at a CAGR of 11.6 % during the forecast period. The Biochemical Testing market is expected to witness a CAGR of 12.2% during (2019 - 2025).
The Diagnostic Testing market dominated the South Africa Genetic Testing Market by Type in 2018, growing at a CAGR of 12.5 % during the forecast period. The Prenatal and Newborn Testing market is expected to witness a CAGR of 12.6% during (2019 - 2025).
Full Report:https://www.kbvresearch.com/lamea-genetic-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Myriad Genetics, Inc., Empire Genomics LLC, Bio-Rad Laboratories, Inc., Novartis AG, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Danaher Corporation, and Abbott Laboratories (Abbott Laboratories Molecular, Inc.).
By Type
By Technology
By Application
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
